83 –1 (29/2) — Ochilova G.S., Musaeva D.M., — INFLUENCE OF MDR-1 GENE POLYMORPHISM ON THE EFFECTIVENESS OF TREATMENT OF CHRONIC GASTRITIS

INFLUENCE OF MDR-1 GENE POLYMORPHISM ON THE EFFECTIVENESS OF TREATMENT OF CHRONIC GASTRITIS

Ochilova G.S., Bukhara State Medical Institute.

Musaeva D.M., Bukhara State Medical Institute.

Resume,

The article notes that the individualization of medicine is an innovative direction that increases the safety and effectiveness of pharmacotherapy, a modern methodology for modernizing the health care system. The novelty of this study lies in the fact that for the first time the activity of P-glycoprotein and the effect of the MDR-1 gene on the effectiveness of drugs used to treat chronic gastritis were studied and a differentiated approach to the treatment of this pathology   was   developed. Knowledge of the      effect of        the R-glycoprotein encoded by the MDR-1 gene on the pharmacokinetics of the drug increases the effectiveness and safety of not only pharmacotherapy, but also the economic and social significance of the treatment.

Key words: pharmacogenetics, P-glycoprotein, MDR-1 genes, chronic gastritis, individual pharmacotherapy.

First page

301

Last page

304

For citation: Ochilova G.S., Musaeva D.M., Influence of mdr-1 gene polymorphism on the effectiveness of treatment of chronic gastritis//New Day in Medicine 1(29)2020 301-304 https://cutt.ly/hvNYHop

List of References

1. Кукес В.Г., Грачев С.В., Сычев Д.А, Раменская Г.В. Метабо­лизм лекарственных средств: научные основы персонализи­рованной медицины. М.- ГЭОТАР-Медиа, 2008. 304 с.
2. Кличова Ф.К., Очилова Г.С. Сборник тезисов II Всероссийс­кой научно- практической конференции с международным участием. Безопасность фармакотерапии: NOLI NOCERE! г. Казан, 16 мая 2019 г.
3. Мусаева Д.М., Очилова Г.С. “Значение гена MDR-1 в фарма­котерапии при хронических гастритах” Проблемы биологии и медицины, 2019, № 4 (113).
4. Мусаева Д.М., Очилова Г.С. “Сурункали гастритни даволашда MDR-1 аллел вариантларининг ахамияти” Материалы между­народной научно- практической онлайн-конференции “Ак­туальные вопросы медицинской науки в XXI веке” г.Ташкент, 25.04.2019г.
5. С.В.Чубарова, АЮ.Крапошина, Е.АСобко, И.В.Демко, А.Б-. Салмина. Физиологические и клинические иаспекты Р-гли- копротеина // Бюллетень. Вып.45. – 2012 г. 91-97 с.
6. Сычев Д.А, Раменская Г.В., Игнатьев И.В., Кукес В.Г. Кли­ническая фармакогенетика. /Под редакцией Кукеса В.Г., Боч­кова Н.П. М.: Гэотар-Медиа, 2007. 248 с.
7. Kim K.A., Park P.W., Park J.Y. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects //Br. J. Clin.Pharmacol. 2007, Jan. Vol.63, №1. P. 53-58.
8. Kim R. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev., 2012, 34, 47-54.
9. Kuzuya T., Kobayashi T., Moriyama N., Nagasaka T., Yokoyama I., UchidaK., Nakao A, NabeshimaT. Amlodipine, but not MDR1polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients //Transplantation. 2003. Vol.76, №5.P. 865-868.
10. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition //Xenobiotica. 2008, Jul. Vol.38, №7-8. P. 802-832.
11. Zhou S.F., Di Y.M., Chan E., Du Y.M., Chow V.D., Xue C.C., Lai X., Wang J.C., Li C.G., Tian M., Duan W. Clinical pharmacogenetics and potential application in personalized medicine // Curr. Drug. Metab. 2008, Oct. Vol.9, №8. P. 738-784.
12. Pharmacogenomics. Ed. M. Rothstein Will-yliss, New Jersey, 2003, 368 p.
13. Sweet D., Bush K., Nigam S. The organic anion transporter family: from physiology to ontogeny and the clinic. Am. J. Physiol. Renal. Physiol., 2001, 281 (2), F1977-F205.